TY  - JOUR
TT  - NANOSIZED DRUG DELIVERY SYSTEMS FOR ALZHEIMER DISEASE  TREATMENT
AU  - Dereli, Nadir
AU  - Gün, Özge
AU  - Hasçiçek, Canan
PY  - 2016
DA  - April
DO  - 10.1501/Eczfak_0000000579
JF  - Journal of Faculty of Pharmacy of Ankara University
JO  - J. Fac. Pharm. Ankara
PB  - Ankara Üniversitesi
WT  - DergiPark
SN  - 1015-3918
SP  - 54
EP  - 73
VL  - 40
IS  - 1
KW  - alzheimer hastalığı
KW  - kan beyin bariyeri
KW  - nanosistemler
KW  - santral sinir sistemi
N2  - Alzheimer disease is a progresive neurodegenerative disease which affects a lot of people worldwide and expected to affect more people in next years, characterized by memory and cognitive disfunctions. According to Alzheimer’s Disease International (ADI) 2015 report almost 46 million people has affected from Alzheimer’s disease or Alzheimer related diseases worldwide. The exact cause of the disease is stil unknown and radical therapy is not possible. Targeting to a specific organ is stil an unsolved problem for neurodegenerative disesases like Alzheimer’s Disease because of the existance of blood brain barrier which is composed of tightly located endothelial cells and restricts the enterance on the unwanted substances to brain. Last developments in nanotechnology promise for solving this problem. It is expected from nanosized BBB drug delivery systems to develop drug delivery performance, improve the brain selectivity with targeting ligands, enhance blood brain barrier (BBB) permeability and decrease neurotoxicity. In this review Alzheimer’s disease, obstacles for the treatment and the role of nanotechnology based drug delivery systems for overcoming this obstacles will be discussed
UR  - https://doi.org/10.1501/Eczfak_0000000579
L1  - https://dergipark.org.tr/tr/download/article-file/424215
ER  -